A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-01

AUTHORS

Mitchell C. Posner, Donna Niedzwiecki, Alan P. Venook, Donna R. Hollis, Hedy L. Kindler, Edward W. Martin, Richard L. Schilsky, Richard M. Goldberg, for the Cancer and Leukemia Group B

ABSTRACT

BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients. METHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study. RESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events. CONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone. More... »

PAGES

158-164

Identifiers

URI

http://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7

DOI

http://dx.doi.org/10.1245/s10434-007-9654-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1002296347

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18008108


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Anti-Idiotypic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cancer Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoembryonic Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycolipids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatectomy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunity, Cellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaccination", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Posner", 
        "givenName": "Mitchell C.", 
        "id": "sg:person.0662666376.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662666376.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "CALGB Statistical Center, Duke University Medical Center, Durham, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niedzwiecki", 
        "givenName": "Donna", 
        "id": "sg:person.0761643572.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of California, San Francisco", 
          "id": "https://www.grid.ac/institutes/grid.266102.1", 
          "name": [
            "University of California at San Francisco, San Francisco, CA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Venook", 
        "givenName": "Alan P.", 
        "id": "sg:person.01347652015.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347652015.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "CALGB Statistical Center, Duke University Medical Center, Durham, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollis", 
        "givenName": "Donna R.", 
        "id": "sg:person.01065623247.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065623247.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kindler", 
        "givenName": "Hedy L.", 
        "id": "sg:person.01072156003.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072156003.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Ohio State University Wexner Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412332.5", 
          "name": [
            "The Ohio State University Medical Center, Columbus, OH"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "Edward W.", 
        "id": "sg:person.01165001257.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165001257.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schilsky", 
        "givenName": "Richard L.", 
        "id": "sg:person.01133375256.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133375256.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of North Carolina at Chapel Hill", 
          "id": "https://www.grid.ac/institutes/grid.10698.36", 
          "name": [
            "University of North Carolina at Chapel Hill, Chapel Hill, NC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goldberg", 
        "givenName": "Richard M.", 
        "id": "sg:person.016472106717.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016472106717.33"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "for the Cancer and Leukemia Group B", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11605-006-0061-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002763338", 
          "https://doi.org/10.1007/s11605-006-0061-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.soc.2007.04.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004059415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/canjclin.57.1.43", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005586480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.8353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012458227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa032691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014051315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-006-9068-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034768212", 
          "https://doi.org/10.1245/s10434-006-9068-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bjs.1800771115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041536693"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2003.s.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041969488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07186-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042406890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/bjs.1800840719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049625308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1958.10501452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058299418"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.1.148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074572225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1076895666", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080143750", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080152639", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.938", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057206"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.5.1788", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083260955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083347281", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01", 
    "datePublishedReg": "2008-01-01", 
    "description": "BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients.\nMETHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study.\nRESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events.\nCONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1245/s10434-007-9654-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693576", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693667", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693361", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693524", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693353", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693347", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693620", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "15"
      }
    ], 
    "name": "A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903", 
    "pagination": "158-164", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0aeeedd4273d35796c2abeacd8a3230ede298d0eed9d47c882ebe1c4ed6d4b54"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18008108"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9420840"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1245/s10434-007-9654-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1002296347"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1245/s10434-007-9654-7", 
      "https://app.dimensions.ai/details/publication/pub.1002296347"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000498.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1245/s10434-007-9654-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1245/s10434-007-9654-7'


 

This table displays all metadata directly associated to this object as RDF triples.

298 TRIPLES      21 PREDICATES      71 URIs      44 LITERALS      32 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1245/s10434-007-9654-7 schema:about N0ec4e01d45fe4003939225c5d0e31bbd
2 N0f5111bab6864167a955b77abce03e35
3 N2510bb0ed3104f1fa436702965113d43
4 N2a92266a15e24f048326e0d12e2416ca
5 N3aee61fcd5864e90850591512e603f28
6 N43603565376b489496a9a3f1a6b17c12
7 N4472510a3fd6470ba314690714fd966e
8 N4ebe4c63de5c493b91ec24597f05e871
9 N6b1fb60a668a44979d3f9e5c9f834814
10 N7eb5111e537147ae8e6e9b5c18568cbe
11 N827390823932418fa950834d36965c9b
12 N973d6f2c2f164583a365c1766da02069
13 N9b046b5ef1db4fa2bd6c7bc4e862422c
14 Nb4c6dc2b8f374e62b7da14257568bb82
15 Nbbcca699c6bd4f2a98157de74c86119e
16 Nc249551f201f4ff59facc0429b00567d
17 Ncaeb7d3383c549c59dbd0de3db7309de
18 Nd10f1782414f44e3a2439ea19d04514b
19 Nd229e3910f194d2f941cea1daf379a0b
20 Nd6a232ef8bb846e2b48cd3510aa544d8
21 Ne7d5a1eae85f4647a9b985b9a2276cb8
22 Ne99f34a4815f411aa4a7ddf0cbd0f4fa
23 Nf5f9b97897b24a07926393aee142fb80
24 anzsrc-for:11
25 anzsrc-for:1112
26 schema:author N3e7c20785d144d2ebacef5f5ac28e4bf
27 schema:citation sg:pub.10.1007/s11605-006-0061-3
28 sg:pub.10.1245/s10434-006-9068-y
29 https://app.dimensions.ai/details/publication/pub.1076895666
30 https://app.dimensions.ai/details/publication/pub.1080143750
31 https://app.dimensions.ai/details/publication/pub.1080152639
32 https://app.dimensions.ai/details/publication/pub.1083347281
33 https://doi.org/10.1002/bjs.1800771115
34 https://doi.org/10.1002/bjs.1800840719
35 https://doi.org/10.1016/j.soc.2007.04.014
36 https://doi.org/10.1016/s0140-6736(98)07186-4
37 https://doi.org/10.1056/nejmoa032691
38 https://doi.org/10.1080/01621459.1958.10501452
39 https://doi.org/10.1200/jco.1997.15.3.938
40 https://doi.org/10.1200/jco.1998.16.5.1788
41 https://doi.org/10.1200/jco.1999.17.9.2889
42 https://doi.org/10.1200/jco.2000.18.1.148
43 https://doi.org/10.1200/jco.2006.06.8353
44 https://doi.org/10.3322/canjclin.57.1.43
45 https://doi.org/10.3816/cbc.2003.s.005
46 schema:datePublished 2008-01
47 schema:datePublishedReg 2008-01-01
48 schema:description BACKGROUND: Patients with curatively resected colorectal cancer hepatic metastases often harbor occult metastatic disease and are at high risk of experiencing recurrence. This patient cohort is ideally suited to test novel therapies such as immunotherapy. We treated patients-post-hepatic resection-with anti-idiotype monoclonal antibody vaccines to the tumor-associated antigens carcinoembryonic antigen (CeaVac) and human milk fat globule (TriAb), both of which are co-expressed in more than 90% of colorectal cancer patients. METHODS: Vaccinations commenced 6-12 weeks post-hepatic resection and consisted of four biweekly treatments of 2 mg CeaVac and TriAb, then monthly treatments for 2 years, then on every other month for 3 years. The primary endpoint was to investigate the proportion of patients recurrence-free at 2 years, and the objective of the study was to demonstrate that at least 58% would be recurrence-free at this time to consider the regimen worthy of further study. RESULTS: Between July 2001 and October 2004, 56 patients were accrued; 52 patients with margin-negative resection were eligible for analysis. Hepatic lobectomy was performed in 56% of patients with a median of one metastasis (range 1-3). Of the 52 eligible patients, 49 were evaluable for the primary end point. Median follow-up was 3.1 years. The proportion of patients recurrence-free at 2 years was 39%, with a lower confidence bound (LCB) of 0.29. Median recurrence-free survival was 16 months. The 2-year overall survival was 94% (95% CI, 0.81, 0.98). Only 10% of patients had documented grade-3 adverse events. CONCLUSIONS: Anti-idiotype monoclonal antibody vaccine therapy with CeaVac and TriAb as an adjuvant to curative resection of colorectal cancer hepatic metastases is well tolerated but did not improve 2-year recurrence-free survival when compared with the expected value of 40% reported for hepatic resection alone.
49 schema:genre research_article
50 schema:inLanguage en
51 schema:isAccessibleForFree false
52 schema:isPartOf Naff23f3d02174f72976c4503c3a7a360
53 Nd989aeecbd904ce391a052440b73588d
54 sg:journal.1105545
55 schema:name A Phase II Prospective Multi-institutional Trial of Adjuvant Active Specific Immunotherapy Following Curative Resection of Colorectal Cancer Hepatic Metastases: Cancer and Leukemia Group B Study 89903
56 schema:pagination 158-164
57 schema:productId N16f043eddaad4515af4661b9f0d55ba8
58 N5e8ed480e4df4c9f86fed50bd0188cc1
59 N9ee1c2348cb94434b1df7f018e62ba80
60 Na587b8c48bba4c93a641506cc6a81005
61 Nf23fe421af1b4c70a701bf9cab000245
62 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002296347
63 https://doi.org/10.1245/s10434-007-9654-7
64 schema:sdDatePublished 2019-04-10T13:12
65 schema:sdLicense https://scigraph.springernature.com/explorer/license/
66 schema:sdPublisher N84fa9e484dc94fb4950ba67068106f36
67 schema:url http://link.springer.com/10.1245/s10434-007-9654-7
68 sgo:license sg:explorer/license/
69 sgo:sdDataset articles
70 rdf:type schema:ScholarlyArticle
71 N07794037f0bd4977bbbb571770d14629 schema:familyName for the Cancer and Leukemia Group B
72 rdf:type schema:Person
73 N0b41b05ac93c48d8bb61911000d5582b rdf:first sg:person.01165001257.49
74 rdf:rest Nc3286c2383b24895adbe31cfcf09bb01
75 N0ec4e01d45fe4003939225c5d0e31bbd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Disease-Free Survival
77 rdf:type schema:DefinedTerm
78 N0f5111bab6864167a955b77abce03e35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Survival Rate
80 rdf:type schema:DefinedTerm
81 N16f043eddaad4515af4661b9f0d55ba8 schema:name nlm_unique_id
82 schema:value 9420840
83 rdf:type schema:PropertyValue
84 N17d7d47e3d31490d96f907be1f1aff12 rdf:first sg:person.016472106717.33
85 rdf:rest N4823ed2c75754bdc91b4dcc5b57233b5
86 N2510bb0ed3104f1fa436702965113d43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Cancer Vaccines
88 rdf:type schema:DefinedTerm
89 N2a92266a15e24f048326e0d12e2416ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Middle Aged
91 rdf:type schema:DefinedTerm
92 N3ad6f642062c4d91858a06608905741a rdf:first sg:person.01065623247.40
93 rdf:rest N539c309f065b49f9a5f42e161af0d1a5
94 N3aee61fcd5864e90850591512e603f28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Male
96 rdf:type schema:DefinedTerm
97 N3e7c20785d144d2ebacef5f5ac28e4bf rdf:first sg:person.0662666376.33
98 rdf:rest N635bf4b7bb0f4ef9adee21cf80607a41
99 N43603565376b489496a9a3f1a6b17c12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Hepatectomy
101 rdf:type schema:DefinedTerm
102 N4472510a3fd6470ba314690714fd966e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Carcinoembryonic Antigen
104 rdf:type schema:DefinedTerm
105 N4823ed2c75754bdc91b4dcc5b57233b5 rdf:first N07794037f0bd4977bbbb571770d14629
106 rdf:rest rdf:nil
107 N4ebe4c63de5c493b91ec24597f05e871 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Immunotherapy
109 rdf:type schema:DefinedTerm
110 N539c309f065b49f9a5f42e161af0d1a5 rdf:first sg:person.01072156003.42
111 rdf:rest N0b41b05ac93c48d8bb61911000d5582b
112 N5e8ed480e4df4c9f86fed50bd0188cc1 schema:name doi
113 schema:value 10.1245/s10434-007-9654-7
114 rdf:type schema:PropertyValue
115 N635bf4b7bb0f4ef9adee21cf80607a41 rdf:first sg:person.0761643572.59
116 rdf:rest N9751133c141c402686a919a343e765eb
117 N6b1fb60a668a44979d3f9e5c9f834814 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Treatment Outcome
119 rdf:type schema:DefinedTerm
120 N7d235ccb72a7436a857e3d761e648e6e schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
121 rdf:type schema:Organization
122 N7eb5111e537147ae8e6e9b5c18568cbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Chemotherapy, Adjuvant
124 rdf:type schema:DefinedTerm
125 N827390823932418fa950834d36965c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Glycoproteins
127 rdf:type schema:DefinedTerm
128 N84fa9e484dc94fb4950ba67068106f36 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N973d6f2c2f164583a365c1766da02069 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antibodies, Anti-Idiotypic
132 rdf:type schema:DefinedTerm
133 N9751133c141c402686a919a343e765eb rdf:first sg:person.01347652015.55
134 rdf:rest N3ad6f642062c4d91858a06608905741a
135 N9b046b5ef1db4fa2bd6c7bc4e862422c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged, 80 and over
137 rdf:type schema:DefinedTerm
138 N9ee1c2348cb94434b1df7f018e62ba80 schema:name readcube_id
139 schema:value 0aeeedd4273d35796c2abeacd8a3230ede298d0eed9d47c882ebe1c4ed6d4b54
140 rdf:type schema:PropertyValue
141 Na587b8c48bba4c93a641506cc6a81005 schema:name dimensions_id
142 schema:value pub.1002296347
143 rdf:type schema:PropertyValue
144 Naff23f3d02174f72976c4503c3a7a360 schema:issueNumber 1
145 rdf:type schema:PublicationIssue
146 Nb4c6dc2b8f374e62b7da14257568bb82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Glycolipids
148 rdf:type schema:DefinedTerm
149 Nbbcca699c6bd4f2a98157de74c86119e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Vaccination
151 rdf:type schema:DefinedTerm
152 Nc249551f201f4ff59facc0429b00567d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Female
154 rdf:type schema:DefinedTerm
155 Nc3286c2383b24895adbe31cfcf09bb01 rdf:first sg:person.01133375256.39
156 rdf:rest N17d7d47e3d31490d96f907be1f1aff12
157 Nc65f69c2b90944bb9b69fd95839b96dd schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
158 rdf:type schema:Organization
159 Ncaeb7d3383c549c59dbd0de3db7309de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Humans
161 rdf:type schema:DefinedTerm
162 Nd10f1782414f44e3a2439ea19d04514b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Aged
164 rdf:type schema:DefinedTerm
165 Nd229e3910f194d2f941cea1daf379a0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Prospective Studies
167 rdf:type schema:DefinedTerm
168 Nd6a232ef8bb846e2b48cd3510aa544d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Adult
170 rdf:type schema:DefinedTerm
171 Nd989aeecbd904ce391a052440b73588d schema:volumeNumber 15
172 rdf:type schema:PublicationVolume
173 Nde45cfcbc52d402aad5da7ca9af5886a schema:name University of Chicago, 5841 S Maryland Avenue (MC5031), 60637, Chicago, IL
174 rdf:type schema:Organization
175 Ne7d5a1eae85f4647a9b985b9a2276cb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Immunity, Cellular
177 rdf:type schema:DefinedTerm
178 Ne99f34a4815f411aa4a7ddf0cbd0f4fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Liver Neoplasms
180 rdf:type schema:DefinedTerm
181 Nf23fe421af1b4c70a701bf9cab000245 schema:name pubmed_id
182 schema:value 18008108
183 rdf:type schema:PropertyValue
184 Nf5f9b97897b24a07926393aee142fb80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Colorectal Neoplasms
186 rdf:type schema:DefinedTerm
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
191 schema:name Oncology and Carcinogenesis
192 rdf:type schema:DefinedTerm
193 sg:grant.2693347 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
194 rdf:type schema:MonetaryGrant
195 sg:grant.2693353 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
196 rdf:type schema:MonetaryGrant
197 sg:grant.2693361 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
198 rdf:type schema:MonetaryGrant
199 sg:grant.2693524 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
200 rdf:type schema:MonetaryGrant
201 sg:grant.2693576 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
202 rdf:type schema:MonetaryGrant
203 sg:grant.2693620 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
204 rdf:type schema:MonetaryGrant
205 sg:grant.2693667 http://pending.schema.org/fundedItem sg:pub.10.1245/s10434-007-9654-7
206 rdf:type schema:MonetaryGrant
207 sg:journal.1105545 schema:issn 1068-9265
208 1534-4681
209 schema:name Annals of Surgical Oncology
210 rdf:type schema:Periodical
211 sg:person.01065623247.40 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
212 schema:familyName Hollis
213 schema:givenName Donna R.
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065623247.40
215 rdf:type schema:Person
216 sg:person.01072156003.42 schema:affiliation Nc65f69c2b90944bb9b69fd95839b96dd
217 schema:familyName Kindler
218 schema:givenName Hedy L.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072156003.42
220 rdf:type schema:Person
221 sg:person.01133375256.39 schema:affiliation N7d235ccb72a7436a857e3d761e648e6e
222 schema:familyName Schilsky
223 schema:givenName Richard L.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133375256.39
225 rdf:type schema:Person
226 sg:person.01165001257.49 schema:affiliation https://www.grid.ac/institutes/grid.412332.5
227 schema:familyName Martin
228 schema:givenName Edward W.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01165001257.49
230 rdf:type schema:Person
231 sg:person.01347652015.55 schema:affiliation https://www.grid.ac/institutes/grid.266102.1
232 schema:familyName Venook
233 schema:givenName Alan P.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347652015.55
235 rdf:type schema:Person
236 sg:person.016472106717.33 schema:affiliation https://www.grid.ac/institutes/grid.10698.36
237 schema:familyName Goldberg
238 schema:givenName Richard M.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016472106717.33
240 rdf:type schema:Person
241 sg:person.0662666376.33 schema:affiliation Nde45cfcbc52d402aad5da7ca9af5886a
242 schema:familyName Posner
243 schema:givenName Mitchell C.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662666376.33
245 rdf:type schema:Person
246 sg:person.0761643572.59 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
247 schema:familyName Niedzwiecki
248 schema:givenName Donna
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761643572.59
250 rdf:type schema:Person
251 sg:pub.10.1007/s11605-006-0061-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002763338
252 https://doi.org/10.1007/s11605-006-0061-3
253 rdf:type schema:CreativeWork
254 sg:pub.10.1245/s10434-006-9068-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1034768212
255 https://doi.org/10.1245/s10434-006-9068-y
256 rdf:type schema:CreativeWork
257 https://app.dimensions.ai/details/publication/pub.1076895666 schema:CreativeWork
258 https://app.dimensions.ai/details/publication/pub.1080143750 schema:CreativeWork
259 https://app.dimensions.ai/details/publication/pub.1080152639 schema:CreativeWork
260 https://app.dimensions.ai/details/publication/pub.1083347281 schema:CreativeWork
261 https://doi.org/10.1002/bjs.1800771115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041536693
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1002/bjs.1800840719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049625308
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.soc.2007.04.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004059415
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0140-6736(98)07186-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042406890
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1056/nejmoa032691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014051315
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1080/01621459.1958.10501452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058299418
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.1997.15.3.938 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057206
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.1998.16.5.1788 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083260955
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.1999.17.9.2889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549924
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2000.18.1.148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074572225
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2006.06.8353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012458227
282 rdf:type schema:CreativeWork
283 https://doi.org/10.3322/canjclin.57.1.43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005586480
284 rdf:type schema:CreativeWork
285 https://doi.org/10.3816/cbc.2003.s.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041969488
286 rdf:type schema:CreativeWork
287 https://www.grid.ac/institutes/grid.10698.36 schema:alternateName University of North Carolina at Chapel Hill
288 schema:name University of North Carolina at Chapel Hill, Chapel Hill, NC
289 rdf:type schema:Organization
290 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
291 schema:name CALGB Statistical Center, Duke University Medical Center, Durham, NC
292 rdf:type schema:Organization
293 https://www.grid.ac/institutes/grid.266102.1 schema:alternateName University of California, San Francisco
294 schema:name University of California at San Francisco, San Francisco, CA
295 rdf:type schema:Organization
296 https://www.grid.ac/institutes/grid.412332.5 schema:alternateName The Ohio State University Wexner Medical Center
297 schema:name The Ohio State University Medical Center, Columbus, OH
298 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...